HDAC9 and malignant colon neoplasm: The effective reduction in overall HDAC activity by Cubisbel also confirmed successful separation of active drug belinostat from the Cu(II) ion in the reducing environment of colon cancer cells for the first time, rendering belinostat free to exhibit its HDAC inhibitory effect.